公开(公告)号：US20240309110A1

公开(公告)日：2024-09-19

申请号：US18526205

申请日：2023-12-01

Applicant: DANMARKS TEKNISKE UNIVERSITET ,  UNIVERSIDAD DE ZARAGOZA ,  Fundación Agencia Aragonesa para la Investigación y el Desarrollo (ARAID)

Inventor： Ola Blixt ,  Ramón Hurtado Guerrero ,  Spyridon Gatos

IPC: C07K16/30 ,  A61K49/00 ,  C07K16/28 ,  C12N15/10

CPC classification number: C07K16/3092 ,  A61K49/0002 ,  C07K16/2896 ,  C12N15/1037 ,  A61K39/00 ,  C07K2317/24 ,  C07K2317/622

Abstract: The invention provides specific Tn- and/or STn antibody libraries and methods for identifying specific antibodies, which target Tn- and/or STn-glycosylation sites of any glycoprotein of choice, especially glycoproteins of cancer cell targets. The invention further provides antibodies identified by the new concept proposed herein, which have combined specificity towards both the sugar epitope as well as the peptide epitope of the glycoprotein.

公开(公告)号：US20240295558A1

公开(公告)日：2024-09-05

申请号：US18656159

申请日：2024-05-06

Applicant: Sona Nanotech Inc.

Inventor： Kulbir Singh ,  Michael McAlduff ,  D. Gerrard Marangoni

IPC: G01N33/574 ,  A61K9/20 ,  A61K41/00 ,  A61K47/68 ,  A61K49/00 ,  B22F1/054 ,  B22F9/24 ,  B82Y5/00 ,  B82Y15/00 ,  B82Y40/00 ,  C07C211/63 ,  C07K14/005 ,  C07K16/00 ,  C07K17/14 ,  G01N33/543

CPC classification number: G01N33/574 ,  A61K9/2072 ,  A61K41/0052 ,  A61K47/6835 ,  A61K49/0002 ,  B22F1/0547 ,  B22F1/0549 ,  B22F9/24 ,  C07C211/63 ,  C07K14/005 ,  C07K16/00 ,  C07K17/14 ,  G01N33/54346 ,  B22F2301/255 ,  B82Y5/00 ,  B82Y15/00 ,  B82Y40/00 ,  C12N2740/16111

Abstract: A method for making metal nanorods comprises combining a source of metal cations with at least one surfactant to form a mixture, wherein the metal cations are reduced and the metal nanorods are produced. Metal nanorods produced by the method and uses thereof. The metal nanorods are useful in devices such as lateral flow devices.

公开(公告)号：US12062422B2

公开(公告)日：2024-08-13

申请号：US17159591

申请日：2021-01-27

Applicant: The Trustees of Columbia University in the City of New York

Inventor： Wei Min ,  Lingyan Shi

IPC: G16H20/10 ,  A61K49/00 ,  G01N21/65 ,  G01N33/68

CPC classification number: G16H20/10 ,  A61K49/0002 ,  A61K49/0004 ,  G01N21/65 ,  G01N33/6848 ,  G01N2021/656 ,  G01N2458/15 ,  G01N2500/10 ,  G01N2570/00

Abstract: Incorporation of deuterium into the lipids, proteins, and/or genetic material in cells, tissues, organs, or organisms, including animals, such as humans, and plants, by administration of heavy water, allows for the spectral determination of levels of lipids, proteins, and/or genetic material using Raman spectroscopy, such as stimulated Raman spectroscopy. Following administration of a drug, changes in the relative amounts of lipid, protein, and/or genetic materials can be determined, and the efficacy, or lack thereof, of the administered drug can be determined.

公开(公告)号：US20240199588A1

公开(公告)日：2024-06-20

申请号：US18550178

申请日：2022-03-21

Applicant: The Hong Kong Polytechnic University

Inventor： Ga-Lai LAW

IPC: C07D403/14 ,  A61K49/00 ,  A61K49/10 ,  A61K51/04 ,  C07D255/02 ,  C07D401/14

CPC classification number: C07D403/14 ,  A61K49/0002 ,  A61K49/106 ,  A61K51/0482 ,  C07D255/02 ,  C07D401/14

Abstract: Cyclic 1,4,7-triazacyclononane-1,4,7-triacetic acid chelators and metal complexes comprising the same useful as positron emission tomography imaging agents, magnetic resonance imaging contrast agents, and computed tomography imaging agents, and optical imaging agents, and methods of use and preparation thereof.

公开(公告)号：US20240174755A1

公开(公告)日：2024-05-30

申请号：US17760252

申请日：2021-02-05

Applicant: BIORION TECHNOLOGIES B.V.

Inventor： Hermannus STEEN ,  Gustaaf Johan Marie VAN SCHARRENBURG

IPC: C07K16/28 ,  A61K45/06 ,  A61K47/68 ,  A61K49/00 ,  A61K51/10

CPC classification number: C07K16/2863 ,  A61K45/06 ,  A61K47/6849 ,  A61K49/0002 ,  A61K51/103 ,  C07K2317/31 ,  C07K2317/35 ,  C07K2317/569

Abstract: The invention relates to antibodies against the Platelet Derived Growth Factor Receptor beta (PDGFR β), and the use thereof in diagnostic and/or therapeutic applications. In particular, it provides a (VHH) antibody that specifically binds PDGFR β with an apparent binding affinity of less than 10 nM, preferably less than 5 nM, and which does not activate PDGFR β. Also provided are PDGFR β antibodies and conjugates thereof, and their application in the targeted delivery of a diagnostic agent, a therapeutic agent or a combination thereof to a tissue in a subject, in particular to fibrotic tissue comprising activated myofibroblasts.

公开(公告)号：US20240148917A1

公开(公告)日：2024-05-09

申请号：US18249192

申请日：2021-10-18

Applicant: Zytox Therapeutics AB

Inventor： Amelie Eriksson Karlström ,  Kristina Westerlund ,  Hanna Tano

IPC: A61K51/08 ,  A61K47/60 ,  A61K47/64 ,  A61K47/66 ,  A61K49/00 ,  A61P35/00

CPC classification number: A61K51/088 ,  A61K47/60 ,  A61K47/64 ,  A61K47/665 ,  A61K49/0002 ,  A61P35/00

Abstract: The invention relates to a kit for targeting of a diagnostic or therapeutic agent to a target site comprising: (a) a first conjugate comprising (i) a targeting moiety capable of binding selectively to the target site; and (ii) a first hybridization probe moiety comprising a PNA oligomer; and (b) a second conjugate comprising (i) a second hybridization probe moiety comprising a complementary PNA oligomer; and (ii) a diagnostic agent or a therapeutic agent moiety; wherein the length of the complementary PNA oligomer in the second hybridization probe moiety is not more than 14 bases. The invention further relates to methods for delivering a diagnostic or therapeutic agent to a target site in mammals, as well as methods for the diagnosis or treatment of medical conditions, such as e.g. cancer, in mammals.

公开(公告)号：US20240132622A1

公开(公告)日：2024-04-25

申请号：US18357007

申请日：2023-07-20

Applicant: Bristol-Myers Squibb Company

Inventor： Lin Hui Su ,  Ekaterina Deyanova ,  Burce Ergel Gurbuzbalaban ,  Mariana Nacht ,  Samantha Elaine Pace ,  Yun Wang ,  Qing Xiao ,  Ramakrishna Chandran ,  Shailesh Dudhgaonkar ,  Michael Louis Doyle ,  Michael Gilman ,  Richard Huang ,  Akbar Nayeem ,  Alok Sharma ,  Qihong Zhao

IPC: C07K16/40 ,  A01N1/02 ,  A61K45/06 ,  A61K47/68 ,  A61K49/00 ,  A61P19/02 ,  A61P37/06

CPC classification number: C07K16/40 ,  A01N1/0226 ,  A61K45/06 ,  A61K47/6871 ,  A61K49/0002 ,  A61P19/02 ,  A61P37/06

Abstract: The present application relates to particular anti-PAD4 (peptidyl arginine deiminase 4) antibodies, nucleic acids encoding the antibodies, vectors and host cells comprising the nucleic acids, and methods of making and using the antibodies.

公开(公告)号：US20240103015A1

公开(公告)日：2024-03-28

申请号：US18477206

申请日：2023-09-28

Applicant: University of Maryland, Baltimore

Inventor： Robert J. Bloch ,  Andrea O'Neill ,  Maria Traficante

IPC: G01N33/68 ,  A61K49/00 ,  C07K16/28

CPC classification number: G01N33/6887 ,  A61K49/0002 ,  C07K16/28 ,  G01N2800/2878

Abstract: The present invention is directed to methods of detecting SLC34A2 expression in muscle tissue in a sample from a subject comprising providing the sample from the subject; and conducting an assay to detect an expression level of SLC34A2 in the sample.

公开(公告)号：US11919972B2

公开(公告)日：2024-03-05

申请号：US16673657

申请日：2019-11-04

Applicant: REGENERON PHARMACEUTICALS, INC.

Inventor： Anders Eliasen

IPC: C07K7/06 ,  A61K49/00 ,  A61K49/14 ,  A61K51/08 ,  C12N15/10 ,  G01N33/68

CPC classification number: C07K7/06 ,  A61K49/0002 ,  A61K49/14 ,  A61K51/08 ,  C12N15/1072 ,  G01N33/68

Abstract: Disclosed are peptides having non-canonical amino acids. These peptides are useful, for example, as protein binding agents. Libraries of such peptides can be used, for example to screen and select protein binding agents. The broader chemical space of the disclosed peptides can provide peptide with different, improved, more specific, and/or pharmaceutically compatible peptides and protein binding agents. In some forms, the peptides can have the following structure (I):




including stereoisomers, pharmaceutically acceptable salts and prodrugs thereof, wherein R, R1, L1, L2, G, M, Y1 Y2 and SEQ are as defined herein. Methods associated with preparation and use of such peptides, as well as pharmaceutical compositions comprising such peptides, are also disclosed.

公开(公告)号：US20230330275A1

公开(公告)日：2023-10-19

申请号：US17990347

申请日：2022-11-18

Applicant: Trustees of Tufts College

Inventor： William W. Bachovchin ,  Hung-sen Lai ,  Wengen Wu

IPC: A61K51/04 ,  A61K49/00

CPC classification number: A61K51/0482 ,  A61K49/006 ,  A61K49/0002 ,  A61K49/0032 ,  A61K49/0052 ,  A61K51/0497

Abstract: The tumor stroma, which accounts for a large part of the tumor mass, represents an attractive target for the delivery of diagnostic and therapeutic compounds. Here, the focus is notably on a subpopulation of stromal cells, known as cancer-associated fibroblasts, which are present in more than 90% of epithelial carcinomas, including pancreatic, colon, and breast cancer. Cancer-associated fibroblasts feature high expression of FAP, which is not detectable in adult normal tissue but is associated with a poor prognosis in cancer patients. The present invention provides small-molecule radiopharmaceutical and imaging agents based on a FAP-specific inhibitor.